Evidence map›Paper›PMID 17050687›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2006

Macrophage inhibitory cytokine 1 mediates a p53-dependent protective arrest in S phase in response to starvation for DNA precursors.

Mukesh K Agarwal, Kedar Hastak, Mark W Jackson, Samuel N Breit, George R Stark, Munna L Agarwal

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 62 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Role of GDF15 (growth and differentiation factor 15) in pulmonary oxygen toxicity.Toxicology in vitro : an international journal published in association with BIBRA · 2015
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Pyrimidine biosynthesis links mitochondrial respiration to the p53 pathway.Proceedings of the National Academy of Sciences of the United States of America · 2010
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Mukesh K AgarwalDepartment of Genetics, Case Western Reserve University, Cleveland, OH 44106, USA. munnaagarwal@hotmail.com
Kedar Hastak
Mark W Jackson
Samuel N Breit
George R Stark
Munna L Agarwal
Case Western Reserve University · USCase Comprehensive Cancer CenterUNSW Sydney · AU

Funding

P53 MODIFICATION AND NOVEL BIOLOGICAL FUNCTIONSR01GM049345 · NIGMS · CLEVELAND CLINIC LERNER COL/MED-CWRU · PI STARK, GEORGE ROBERT · 1993 to 2006
$2.5M
Functional analysis of signaling to and from p53 in cancerR01CA098916 · NCI · CLEVELAND CLINIC FOUNDATION · PI AGARWAL, MUNNA L. · 2003 to 2007
$1.3M
NCI NIH HHS CA 98916NCI NIH HHS R01 CA098916NIGMS NIH HHS GM 49345NIGMS NIH HHS R01 GM049345
6 · The paper itself

Abstract

p53 is essential for the cellular responses to DNA damage that help to maintain genomic stability. Protective p53-dependent cell-cycle checkpoints are activated in response to a wide variety of stresses, including not only DNA damage but also arrest of DNA synthesis and of mitosis. In addition to its role in activating the G(1) and G(2) checkpoints, p53 also helps to protect cells in S phase when they are starved for DNA precursors by treatment with the specific aspartate transcarbamylase inhibitor N-phosphonacetyl-l-aspartate (PALA), which blocks the synthesis of pyrimidine nucleotides. Even though p53 is activated, PALA-treated cells expressing low levels of p53 or lacking expression of p21 do not arrest in G(1) or G(2) but are blocked in S phase instead. In the complete absence of p53, PALA-treated cells continue to synthesize DNA slowly and eventually progress through S phase, suffering severe DNA damage that in turn triggers apoptosis. Expression of the secreted protein macrophage inhibitory cytokine 1 (MIC-1), a member of the TGF-beta superfamily, increases substantially after PALA treatment, and application of exogenous MIC-1 or its constitutive expression from a cDNA provides remarkable protection of p53-null cells from PALA-mediated apoptosis, arguing that the p53-dependent secretion of MIC-1 provides a major part of such protection. Stimulation of MIC-1-dependent S phase arrest in normal gut epithelial cells might help to revitalize the clinical use of PALA, which has been limited by gut toxicity.

Indexed as

S PhaseApoptosisAspartic AcidCell LineCytokinesDNAEpithelial CellsGene Expression Regulation, NeoplasticGrowth Differentiation Factor 15HumansPhosphonoacetic AcidSignal TransductionTumor Suppressor Protein p53Aspartic AcidCytokinesDNAGDF15 protein, humanGrowth Differentiation Factor 15Phosphonoacetic Acidsparfosic acidTumor Suppressor Protein p53

Identifiers

PMID17050687
PMCPMC1637573
OpenAlexW2058073881

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.